• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    7/18/23 5:32:39 PM ET
    $AMRN
    $APRE
    $ARDS
    $ETAO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMRN alert in real time by email

    Gainers

    • Etao International Co (NASDAQ:ETAO) shares rose 10.3% to $0.48 during Tuesday's after-market session. The market value of their outstanding shares is at $49.1 million.
    • Virax Biolabs Group (NASDAQ:VRAX) shares rose 8.37% to $0.44. The market value of their outstanding shares is at $7.8 million.
    • Aprea Therapeutics (NASDAQ:APRE) stock increased by 7.14% to $3.75. The market value of their outstanding shares is at $13.9 million.
    • Reneo Pharmaceuticals (NASDAQ:RPHM) shares moved upwards by 5.62% to $7.14. The company's market cap stands at $240.3 million.
    • Ra Medical Systems (AMEX:RMED) shares moved upwards by 5.57% to $0.75. The company's market cap stands at $4.8 million.
    • Mesoblast (NASDAQ:MESO) stock rose 5.0% to $5.04. The market value of their outstanding shares is at $820.1 million.

    Losers

    • Amarin Corp (NASDAQ:AMRN) shares declined by 10.5% to $1.28 during Tuesday's after-market session. Today's trading volume for this security ended up closing at 424.1K shares, which is 20.8 percent of its average volume over the last 100 days. The company's market cap stands at $521.9 million.
    • EUDA Health Holdings (NASDAQ:EUDA) stock decreased by 10.17% to $0.45. At the close, EUDA Health Holdings's trading volume reached 281.8K shares. This is 60.2% of its average volume over the last 100 days. The company's market cap stands at $11.1 million.
    • ViewRay (NASDAQ:VRAY) stock fell 8.6% to $0.08. Today's trading volume for this security ended up closing at 22.1 million shares, which is 361.9 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $14.8 million.
    • Aridis Pharmaceuticals (NASDAQ:ARDS) stock fell 7.68% to $0.29. At the close, Aridis Pharmaceuticals's trading volume reached 15.2 million shares. This is 373.6% of its average volume over the last 100 days. The company's market cap stands at $10.3 million.
    • Oncology Institute (NASDAQ:TOI) shares declined by 5.7% to $0.73. The company's market cap stands at $55.0 million.
    • Theriva Biologics (AMEX:TOVX) stock fell 5.65% to $0.66. The company's market cap stands at $9.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AMRN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMRN
    $APRE
    $ARDS
    $ETAO

    CompanyDatePrice TargetRatingAnalyst
    Mesoblast Limited
    $MESO
    11/25/2025Hold → Buy
    Jefferies
    The Oncology Institute Inc.
    $TOI
    11/25/2025$5.00Buy
    Needham
    The Oncology Institute Inc.
    $TOI
    7/23/2025$8.00Outperform
    Noble Capital Markets
    Mesoblast Limited
    $MESO
    7/18/2025Buy → Hold
    Jefferies
    The Oncology Institute Inc.
    $TOI
    7/16/2025$6.00Buy
    B. Riley Securities
    The Oncology Institute Inc.
    $TOI
    5/15/2025$7.00Buy
    BTIG Research
    Virax Biolabs Group Limited
    $VRAX
    3/31/2025$3.00Buy
    H.C. Wainwright
    Mesoblast Limited
    $MESO
    12/23/2024Buy → Hold
    Jefferies
    More analyst ratings

    $AMRN
    $APRE
    $ARDS
    $ETAO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mesoblast upgraded by Jefferies

    Jefferies upgraded Mesoblast from Hold to Buy

    11/25/25 8:34:05 AM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Needham initiated coverage on The Oncology Institute with a new price target

    Needham initiated coverage of The Oncology Institute with a rating of Buy and set a new price target of $5.00

    11/25/25 8:00:05 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Noble Capital Markets initiated coverage on The Oncology Institute with a new price target

    Noble Capital Markets initiated coverage of The Oncology Institute with a rating of Outperform and set a new price target of $8.00

    7/23/25 9:21:53 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $AMRN
    $APRE
    $ARDS
    $ETAO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement

    DOYLESTOWN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced the closing of its previously announced oversubscribed private placement financing. Total gross proceeds from the offering are approximately $30 million to the Company before deducting placement agent fees and other private placement expenses (the "Offering"). The Offering closed on March 31, 2026. The Company intends to use the upfront net proceeds for general corporate purposes and for research a

    4/1/26 8:30:00 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation

    LONDON, March 31, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company") today announced that Virax Biolabs (UK) Limited, its wholly owned subsidiary, has achieved ISO 13485:2016 and ISO 9001:2015 certification for its quality management system. The certifications were issued by LRQA, with an issue date of 18 February 2026 and an expiry date of 17 February 2029. Highlights:Virax believes the strengthened quality framework supports its post-acute infection syndromes ("PAIS") strategy by strengthening readiness for regulated in vitro diagnostic (

    3/31/26 7:34:00 AM ET
    $VRAX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement

    Financing led by Soleus Capital with participation from Vestal Point Capital, Squadron Capital Management and additional new and existing investors DOYLESTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that it has entered into a securities purchase agreement for an oversubscribed private placement financing that is expected to result in total gross proceeds of approximately $30 million to the Company before deducting placement agent fees and other pr

    3/30/26 8:01:00 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRN
    $APRE
    $ARDS
    $ETAO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Fishman Peter L.

    4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

    4/2/26 4:30:11 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Langsam Jeffrey

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    4/1/26 9:00:00 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by England Kristin

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    4/1/26 8:57:33 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $AMRN
    $APRE
    $ARDS
    $ETAO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Chernett Jorey bought $1,225,101 worth of shares (398,985 units at $3.07), increasing direct ownership by 4% to 10,251,929 units (SEC Form 4)

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    3/17/26 7:40:00 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    President/CEO Gilad Oren bought $25,009 worth of shares (28,100 units at $0.89), increasing direct ownership by 8% to 373,720 units (SEC Form 4)

    4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

    2/2/26 4:08:08 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SrVP/CFO/Prin Fin & Acct Ofcr Hamill John P. bought $5,073 worth of shares (5,700 units at $0.89), increasing direct ownership by 21% to 33,433 units (SEC Form 4)

    4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

    2/2/26 4:05:34 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRN
    $APRE
    $ARDS
    $ETAO
    SEC Filings

    View All

    Aprea Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Aprea Therapeutics, Inc. (0001781983) (Filer)

    4/1/26 8:45:47 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by Amarin Corporation plc

    PRE 14A - AMARIN CORP PLC\UK (0000897448) (Filer)

    3/30/26 5:57:06 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aprea Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Aprea Therapeutics, Inc. (0001781983) (Filer)

    3/30/26 5:30:52 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRN
    $APRE
    $ARDS
    $ETAO
    Leadership Updates

    Live Leadership Updates

    View All

    Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

    Early clinical proof-of-concept for WEE1 inhibitor APR-1051 in the ongoing ACESOT-1051 trial with two partial responders at first scan in endometrial cancer patients with PPP2R1A mutationClinical team strengthened with the appointment of Eugene (Gene) Kennedy, MD, as Chief Medical Advisor to support next phase of clinical developmentCapital is in place to support key milestones, including additional enrollment of patients at key dose levels in ongoing ACESOT-1051 trial DOYLESTOWN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targe

    3/16/26 8:00:00 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast

    NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the appointment of Teresa Montagut MD, PhD in the newly established position of Head of Clinical Development and Medical Affairs reporting to the Chief Medical Officer Dr. Eric Rose. In this role, Teresa will lead Mesoblast's medical affairs organization, fostering clinical collaborations and spearheading investigator-initiated trials, enhancing clinical and medical communications, and engaging with healthcare professionals. She will play a critical role in unlocking the value of Mesoblast's cell therapy programs i

    3/11/26 7:21:39 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    The Oncology Institute Appoints Kim Tzoumakas to Board of Directors

    CERRITOS, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced the appointment of Kim Tzoumakas to its Board of Directors, effective February 23, 2026. Ms. Tzoumakas brings more than two decades of executive leadership experience across oncology, pharmacy services and healthcare operations. Notably, she is Chief Executive Officer for VytlOne National Pharmacy Services, and previously held the CEO role at 21st Century Oncology, where she successfully led the organization through a multi-year operational turnaround, culminating in its strategic sale. She also has serve

    2/23/26 8:00:00 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $AMRN
    $APRE
    $ARDS
    $ETAO
    Financials

    Live finance-specific insights

    View All

    The Oncology Institute Reports Fourth Quarter and Full Year 2025 Financial Results and Guidance for 2026

    CERRITOS, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and year ended December 31, 2025. Recent Operational Highlights Cash flow from operations in Q4 2025 was approximately $3.2 million, due to disciplined working capital management and overall increase in gross profit marginContinued expansion of our capitated footprint, initiating 9 new capitated contracts during 2025 in CA, FL, and NV, representing approximately 260,000 additional lives under managementFurther ramped our capitation

    3/12/26 4:05:00 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results

    - Advancing clinical development of VCN-01 for pancreatic ductal adenocarcinoma and retinoblastoma - - Licensed SYN-020 to Rasayana Therapeutics for development in multiple indications; up to $38 million in potential milestones plus royalties on commercial sales - - Cash and cash equivalents of $13.1 million as of December 31, 2025; recent capital raises increase cash to $15.2 million as of February 26, 2026 and provides cash runway into Q1 2027- ROCKVILLE, M.D., March 12, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE:TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported fin

    3/12/26 8:00:00 AM ET
    $TOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Oncology Institute Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Conference Call

    CERRITOS, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI)  a pioneer in value-based community oncology care, today announced that the company will release its fourth quarter and full year 2025 financial results on Thursday, March 12, 2026, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 13758646. The

    2/26/26 8:00:00 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $AMRN
    $APRE
    $ARDS
    $ETAO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

    SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

    12/16/24 12:08:07 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Aridis Pharmaceuticals Inc.

    SC 13G/A - Aridis Pharmaceuticals, Inc. (0001614067) (Subject)

    11/14/24 4:46:40 PM ET
    $ARDS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Virax Biolabs Group Limited

    SC 13G/A - Virax Biolabs Group Ltd (0001885827) (Subject)

    11/14/24 4:46:07 PM ET
    $VRAX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care